HIV/AIDS news from FierceBiotech
NewsIn fresh blow, Roche shutters HIV research program
In another big blow to the AIDS research field, pharma giant Roche is dumping its R&D work in the field. The Financial Times reports that disappointing clinical results had persuaded Roche to Read more...
Trimeris' shareholder calls for sale of developer
Once one of the Triangle's most promising drug developers, Trimeris' largest shareholder is demanding that the company drop just about everything and focus on selling itself. "We are not in favor of Read more...
Offshoring clinical trials raises harsh criticisms
The rapid move toward offshoring drug trials has sparked controversies over the ethics involved in some of these studies, reports the Financial Times. Take for instance California's Viral Genetics, Read more...
ALSO NOTED: CEO: Novartis plans big restructuring; Time notes advances in stem cells, genetics; MabThera trials produce positiv
> In October, Novartis announced some job cuts and management changes. Now, CEO Daniel Vasella says he's working on a sweeping overhaul of his company's org chart. Read more...
Long delay seen for Merck's AIDS vaccine
The fallout over Merck's disastrous AIDS vaccine trial continues. There are new Read more...
SPOTLIGHT: Merck scraps AIDS vaccine
Over the weekend Merck announced that it was scrapping development of a promising AIDS vaccine after researchers concluded that it had failed a large international study. This was considered a major Read more...
FDA panel endorses Merck's new AIDS drug
An FDA expert panel has provided an important endorsement for Merck's experimental AIDS drug Isentress. The twice-a-day pill is the first in a new class of AIDS drugs. If fully approved by the Read more...
Tobira garners $31M to advance HIV drugs
Up-start biotech Tobira Therapeutics, which is developing HIV/AIDS drugs, has raised $31 million in its first round of venture capital. Domain Associates and Frazier Healthcare Ventures led the round Read more...
ALSO NOTED: Advanced Magnetics touts Phase III data; MicroIslet makes staffing changes; and much more...
> Advanced Magnetics has announced preliminary positive results from its fourth and final planned Phase III clinical trial of ferumoxytol as an intravenous iron replacement therapeutic in chronic Read more...
Altus loses orphan drug statusThe FDA on Tuesday yanked Altus Pharmaceuticals' orphan drug designation for its experimental pancreatic insufficiency therapy, saying the number of patients with the condition exceeds the 200,000 mark required for an orphan drug. The drug--ALTU-135--is intended to treat a rare condition in which a person fails to develop the chemicals and enzymes needed to absorb food. Altus officials say they may consult with the agency about refilling an application. "We believe that only a … Read more... | Press ReleasesPRESS RELEASE: MSD grants Adcock Ingram a license to manufacture and supply efavirenz MSD grants Adcock Ingram a license to manufacture and supply efavirenz, an antiretroviral medicine for the treatment of HIV infection Merck & Co., Inc., Whitehouse Station, New Jersey (which Read more... PRESS RELEASE: FDA Advisory Committee Unanimously Recommends Accelerated Approval of ISENTRESS FDA Advisory Committee Unanimously Recommends Accelerated Approval of ISENTRESS™ (raltegravir), Merck's Investigational Oral Integrase Inhibitor, for Treatment of HIV WHITEHOUSE STATION, N.J., Read more... PRESS RELEASE: Presidio Pharmaceuticals Closes $26 Million Series B Financing Presidio Pharmaceuticals Closes $26 Million Series B Financing SAN FRANCISCO -- Presidio Pharmaceuticals, Inc, a specialty pharmaceutical company focused on developing and commercializing novel, Read more... |
Get more HIV/AIDS coverage at:
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets

